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meaningful. This equated to the change found following six-
months of treatment.
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OBJECTIVES: Monetary cost, positive values truncated at zero,
violates normality assumption when used as the dependent 
variable in ordinary least squares (OLS) regressions. Log trans-
formation of cost removes the skewness, but the resulting coef-
ﬁcients are not directly interpretable as raw dollars. Simply
taking exponent of ﬁtted regression coefﬁcients causes retrans-
formation bias. Duan’s nonparametric smearing estimator
factors into the mean of the anti-log of the residuals, thus 
correcting retransformation bias. The goal of this analysis is to
apply Duan’s smearing technique to retransform logged costs to
evaluate the incremental cost of ChHD using claims data from
an HMO. METHODS: A 13-item self-assessment questionnaire
identifying ChHD and its severity was developed, validated, and
mailed to 1,380 randomly selected members of a Massachusetts
HMO. Average monthly costs for questionnaire respondents
were calculated by the sum of approved and co-payment
amounts from claims ﬁled between April 1, 2001–December 31,
2003 divided by months of observation. OLS regression of log-
arithm of cost was used, with covariates consisting of a ChHD
dummy, and demographic and co-morbid factors. Using Duan’s
estimator, average monthly incremental cost of ChHD was cal-
culated by multiplying percentage cost increase for ChHD from
the OLS regression by predicted average monthly cost for Non-
ChHD patients (which is the average cost after removing the
effect of the ChHD dummy). RESULTS: 140 of 507 question-
naire respondents were identiﬁed as ChHD. Univariate compar-
ison showed no statistical difference in monthly cost between the
ChHD and Non-ChHD groups (Non-ChHD, $326.98 ± $29.52,
ChHD $270.87 ± $23.59, p = 0.1383). A skewness and kurto-
sis test rejected normality. However, multivariate analysis
showed that ChHD patients had a statistically signiﬁcant
monthly cost increase of 25.2%( ±2.5%) compared to Non-
ChHD (p < 0.001), amounting to an average monthly incre-
mental cost of ChHD of $70.69 (±$7.00) per patient.
CONCLUSIONS: Duan’s smearing estimator may be valid for
inferring incremental cost in OLS regression models of logarithm
of cost.
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OBJECTIVES: Atopic dermatitis (AD) is a common childhood
chronic skin condition. Despite high disease prevalence, up to
20% in some populations, little information is available regard-
ing the burden of disease to children and parent/caregivers. 
An objective of this study was to assess the impact of AD on
parents’/caregivers’ quality-of-life. METHODS: In total, 414 AD
patients, between 2–12 years old were identiﬁed through a ret-
rospective review of outpatient billing records from January,
2001 to December, 2004 from two large physician practices and
were contacted to enroll in the study. Data collected included
patient demographics, comorbidities, treatments, and health 
care resource use. Parents also completed the Parent’s Index of
Quality of Life-Atopic Dermatitis (PIQoL-AD), a 28-item, vali-
dated questionnaire evaluating parents’ needs-based quality-of-
life. Total PIQoL-AD scores can range from zero to 28, with a
higher score indicating greater impaired quality-of-life. One-way
analysis of variance was used to determine statistical signiﬁcance.
RESULTS: Mean patient age was 6.7 (SD ± 3.3) years and 55%
of patients were males. Mean duration and treatment of illness
were 3.0 ± 2.2 years and 20.7 ± 21.4 months, respectively.
Parents’ assessment of disease severity indicated that 82% of
patients had mild AD and 13% of patients had moderate AD.
Patients reporting at least one ﬂare experienced 2.8 ± 2.3 ﬂares
per month; mean duration of ﬂares was 5.2 ± 7.0 days. Disease
ﬂares negatively impacted parents’ quality-of-life. PIQoL-AD
scores worsened among those parents whose child had disease
ﬂares. Mean PIQoL-AD scores were statistically signiﬁcantly
higher (5.9 ± 5.4 vs. 3.0 ± 3.6, p < 0.0001) for those parents
whose child had disease ﬂares compared to those who did 
not have disease ﬂares. CONCLUSIONS: Study ﬁndings will
improve our understanding of the impact of AD on children and
their parents/caregivers and may enhance treatment effects, 
clinical outcomes, and patient and parent/caregiver education.
Further investigation is needed to understand the impact of
atopic dermatitis on parents’ quality-of-life.
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OBJECTIVES: The prevalence of chronic hand dermatitis
(ChHD) and its impact on patient-reported outcomes, including
quality of life (QoL), work and activity impairment, were eval-
uated in a managed care organization (MCO). To date, few
studies have investigated ChHD using a general population-
based approach. METHODS: A validated cross-sectional
patient-reported survey was mailed to 1380 members of a Mass-
achusetts MCO. The survey consisted of: a 13-item clinical ques-
tionnaire identifying ChHD based on signs and symptoms of
dermatitis related to hands, treatment response, and diagnoses
of exclusion; the Skindex-29, a 29-question dermatology-speciﬁc
QoL instrument; and the Work Productivity and Activity Impair-
ment (WPAI) instrument validated for ChHD. Those receiving
the survey were randomly sampled from the general MCO pop-
ulation and a subset population with ≥ two medical claims with
a dermatitis or eczema diagnosis (ICD-9 692 or 691.8). ChHD
patients were compared to patients with other skin conditions
and to Non-ChHD patients to assess their relative QoL and
WPAI measures, respectively. RESULTS: Based on the survey
respondents (36.7% response rate), the prevalence of ChHD 
was 17.5% in the MCO general population, a rate much higher
than previously found (2–12%). QoL and WPAI measures for
the ChHD patients were signiﬁcantly worse than those for their
comparison groups (Skindex score: ChHD = 30.33 ± 17.51,
Other Skin Conditions = 20.05 ± 16.68; Work Impairment:
ChHD = 29.33%, Non-ChHD = 6.85%; Activity Impairment:
ChHD = 33.78%, Non-ChHD = 17.32%; all p < 0.0001).
